公开(公告)号：JPS5993032A

公开(公告)日：1984-05-29

申请号：JP20026882

申请日：1982-11-17

Applicant: TOA EIYO LTD

Inventor： NARA TAKESHI ,  NISHINOMIYA YOUZOU ,  SATOU KENTAROU ,  KAMIKAMA KANEHITO

IPC: C08B37/16 ,  A61K47/40 ,  C07C67/00 ,  C07C201/00 ,  C07C201/02 ,  C07C201/16 ,  C07C203/02 ,  C07C203/04

Abstract: PURPOSE:The titled stable and easily handleable inclusion compound useful as a drug, capable of relieving irritation and preventing volatility, having high safety for tableting, molding, etc., obtained by including an isosorbidnitrate with cyclodextrin. CONSTITUTION:An isosorbidnitrate having a coronary blood vasodilating action, a dinitro ester or mononitro ester derivative of isosorbidnitrate widely used as a remedy and preventive for attack of angine pectoris in the form of a sublingual tablet, oral drug, sustained release drug, injection, etc., is dissolved or dispersed into a solvent containing preferably an equimolar amount of cyclodextrin and water, and the solvent is eliminated to give an isosorbidnitrate- cyclodextrin inclusion compound. alpha-, beta- and gamma-cyclodextrin, a cyclic oligosaccharide called cycloamylose, etc., comprising 6-8 constitutional units of D- glucopyranoses is used as the cyclodextrin.

公开(公告)号：JPH06134357A

公开(公告)日：1994-05-17

申请号：JP30799092

申请日：1992-10-22

Applicant: TOA EIYO LTD

Inventor： SATOU KENTAROU ,  MIYATAKE HIROMITSU

IPC: B05B11/00

Abstract: PURPOSE:To specify a nozzle at a prescribed position and to enable operations for opening and closing of a lid and the depression of a pressing button with one hand. CONSTITUTION:An engaging means 19 is formed on a pressing button member 10 having a nozzle 18 communicated with the valve stem 5 of a valve device 3 built in a spray vessel 1, and also an engaging guide means 29 is formed on a cap member 20 for guiding the pressing button member 10 in a moving direction, and an index is provided on the cap member 20 by allowing the position to correspond to the nozzle 18 whose position in the circumferential direction is defined by relatively engaging these engaging means 19 with an engaging guide means 29. The cap 31 is molded on the cap member 20 integrally via a thin hinge part 30, and the confronting angle of the hinge part 30 and the index is made to be 90 deg.-180 deg.. Thus the injection direction is not missed. The handling is simple and the loss of the lid is prevented.

公开(公告)号：JPS60181052A

公开(公告)日：1985-09-14

申请号：JP3618084

申请日：1984-02-29

Applicant: TOA EIYO LTD

Inventor： NARA TAKESHI ,  HAYASHI HISASHI ,  SATOU KENTAROU

IPC: C07C201/02 ,  C07C67/00 ,  C07C201/00 ,  C07C201/16 ,  C07C203/02 ,  C07C203/04

Abstract: PURPOSE:To provide the titled composition having high stability and handleability, free from irritation and volatility, and effective as a remedy and preventive for the fit of stenocardia, by compounding isosorbide nitrate with a specific component such as polyvinyl pyrrolidone. CONSTITUTION:Isosorbide nitrate is compounded with one or more components selected from the group of polyvinyl pyrrolidone, methyl-cellulose, hydroxypropylcellulose and hydroxypropylmethylcellulose. The amount of the latter component is 0.2-30pts.wt., especially 1-15pts.wt. per 1pt.wt. of isosorbide nitrate. The composition is prepared preferably by dissolving isosorbide nitrate in a solvent, and then dissolving and/or dispersing the latter component such as polyvinyl pyrrolidone in the solution, however, it may be prepared by mixing the solution or dispersion of isosorbide nitrate with the of the latter component.

公开(公告)号：JPS6219531A

公开(公告)日：1987-01-28

申请号：JP15594885

申请日：1985-07-17

Applicant: TOA EIYO LTD

Inventor： NARA TAKESHI ,  NISHINOMIYA YOZO ,  SATOU KENTAROU ,  HAYASHI HISASHI

IPC: A61K38/00 ,  A61K47/00 ,  A61K47/12 ,  A61K47/18 ,  A61K47/36 ,  A61K47/42

Abstract: PURPOSE:To provide the titled drug preparation containing human-type angiotensin in combination with a specific stabilizing agent and useful as a hypertensive agent. CONSTITUTION:The objective human-type angiotensin agent contains (A) human- type angiotensin and (B) one or more stabilizers selected from gelatin, albumin, acidic polysaccharide (e.g. chondroitin sulfate, dextran sulfate, heparin, etc.), acidic amino acid (e.g. glutamic acid, aspartic acid, etc.) and organic acid (e.g. citric acid, lactic acid, tartaric acid, malic acid, etc.). The amounts of gelatin and albumin are preferably 1-1,000pts.wt., and the amounts of the other components are 1-500pts.wt. each per 1pt.wt. of angiotensin. EFFECT:Since the decomposition of angiotensin in the dissolved solution is suppressed and the stability of angiotensin is improved remarkably, the agent is convenient for production, treatment and storage.